With its significant cash infusions from offloading its COVID assets, Novavax had just over $1 billion as it exited Q3, 2024.

Stay updated on the latest potential FDA drug approvals in 2025, including an expanded label for Ozempic and new, nonopioid painkillers.

The Louisiana Department of Health on Monday reported the first human death in the U.S. related to the H5N1 bird flu virus.

Although the stock market was having a generally strong week, that isn't the case for vaccine technology company Moderna ...

These awards were approved by the Compensation C Novavax, Inc. (Nasdaq ... and stand-alone influenza vaccine candidates. The FDA has cleared the Company to begin enrolling the planned Phase ...

A third player in the market, Novavax, filed for approval of a non-mRNA vaccine based on the earlier JN.1 variant before the FDA asked manufacturers to switch to KP.2. However, it said it is ...

Moderna advances combo vaccine for flu and COVID-19 with trials starting in March Pharmaceutical companies gear up to tackle ...

Novavax is working with the FDA to explore a pathway for accelerated approval of the COVID-19-flu combination and standalone flu vaccines. Novavax, Inc. (Nasdaq: NVAX), a global company advancing ...

In the latest trading session, Novavax (NVAX) closed at $8.55, marking a +0.53% move from the previous day. The first human bird flu death in the US has Moderna's vaccine development in focus for ...

When the strain guidance was issued, upending that assumption, Novavax didn’t have time to switch gears. Its vaccine, which ...

The first human bird flu death in the US has Moderna's vaccine development in focus for investors this week. Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it ...